Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer

Qu, Mei-Hua; Zeng, Ruolan; Fang, Shi; Dai, Qiangsheng; Li, Heping; Long, Jianting

doi:10.1016/j.ijpharm.2014.08.019

Cited by 100 publications

(60 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The co-delivery liposomes realized enhanced tumor targeting, better control of tumor volume and inhibition of neovascularization on mice-bearing MCF-7 in situ breast tumor [61] MEK inhibitor PD0325901 and MCL1 siRNA Cationic liposome -The co-delivery liposomes achieved remarkable improvement in the inhibition of tumor growth on xenograft mice model, compared with single agent-loaded liposomes [62] Docetaxel and BCL-2 siRNA Pegylated cationic liposome -Treatment with the co-delivery liposomes resulted in a significant reduction in tumor volume of the mice-bearing A549 cell xenograft tumor and a 100% survival rate in 25 days [63] Mitoxantrone (MTO) and…”

Section: Vapreotidementioning

confidence: 99%

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Zhao

Feng

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

A major problem in cancer treatment is the multidrug resistance. siRNA inhibitors have great advantages to solve the problem, if the bottleneck of their delivery could be well addressed by the various nanocarriers. Moreover, co-delivery of siRNA together with the various anticancer agents in one nanocarrier may maximize their additive or synergistic effect. This review provides a comprehensive summary on the state-of-the-art of the nanocarriers, which may include prodrugs, micelles, liposomes, dendrimers, nanohydrogels, solid lipid nanoparticles, nanoparticles of biodegradable polymers and nucleic acid nanocarriers for delivery of siRNA and co-delivery of siRNA together with anticancer agents with focus on synthesis of the nanocarrier materials, design and characterization, in vitro and in vivo evaluation, and prospect and challenges of nanocarriers.

show abstract

Section: Vapreotidementioning

confidence: 99%

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Zhao

Feng

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…26 Qu et al co-delivered chemotherapeutic drug (doxorubicin [DOX]) and small interfering RNA within a liposome to suppress the tumor growth. 27 Shi et al developed multifunctional star-shaped micelles by combining active targeting with redox-responsive payload release. 28 Dong et al constructed folate-conjugated and pH-responsive micelles loaded with vascular endothelial growth factor targeting small interfering RNA and DOX.…”

Section: Introductionmentioning

confidence: 99%

Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells

Hong

Shi

Qiao

et al. 2017

IJN

View full text Add to dashboard Cite

Even though a tremendous number of multifunctional nanocarriers have been developed to tackle heterogeneous cancer cells, little attention has been paid to elucidate how to rationally design a multifunctional nanocarrier. In this study, three individual functions (active targeting, stimuli-triggered release and endo-lysosomal escape) were evaluated in doxorubicin (DOX)-sensitive MCF-7 cells and DOX-resistant MCF-7/ADR cells by constructing four kinds of micelles with active-targeting (AT-M), passive targeting, pH-triggered release ( pH T-M) and endo-lysosomal escape ( endo E-M) function, respectively. AT-M demonstrated the strongest cytotoxicity against MCF-7 cells and the highest cellular uptake of DOX due to the folate-mediated endocytosis. However, AT-M failed to exhibit the best efficacy against MCF-7/ADR cells, while endo E-M exhibited the strongest cytotoxicity against MCF-7/ADR cells and the highest cellular uptake of DOX due to the lowest elimination of DOX from the cells. This was attributed to the carrier-facilitated endo-lysosomal escape of DOX, which avoided exocytosis by lysosome secretion, resulting in an effective accumulation of DOX in the cytoplasm. The enhanced elimination of DOX from the MCF-7/ADR cells also accounted for the remarkable decrease in cytotoxicity against the cells of AT-M. Three micelles were further evaluated with MCF-7 cells and MCF-7/ADR-resistant cells xenografted mice model. In accordance with the in vitro results, AT-M and endo E-M demonstrated the strongest inhibition on the MCF-7 and MCF-7/ADR xenografted tumor, respectively. Active targeting and active targeting in combination with endo-lysosomal escape have been demonstrated to be the primary function for a nanocarrier against doxorubicin-sensitive and doxorubicin-resistant MCF-7 cells, respectively. These results indicate that the rational design of multifunctional nanocarriers for cancer therapy needs to consider the heterogeneous cancer cells and the primary function needs to be integrated to achieve effective payload delivery.

show abstract

“…Moreover, lipo-DTX/siRNA exhibited greater apoptotic populations and a superior caspase activity than comparing to lipo-DTX throughout the study period. In vivo antitumor study exhibited a significant tumour regression profile for lipo-DTX/siRNA with 100% survival rate, which never occurred with any other treatment option (Qu et al, 2014). All these experiments and results highlight the synergistic antitumour activity of co-loaded siRNA and drug.…”

Section: Sirna/drug Co-deliverymentioning

confidence: 76%

siRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery

Gomes¹,

Martins²,

Sarmento³

2015

Ageing Research Reviews

View full text Add to dashboard Cite

Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer

Cited by 100 publications

References 29 publications

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells

siRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery

Contact Info

Product

Resources

About